-- Human Genome Sciences, Oshkosh, Pfizer: U.S. Equity Preview
-- B y   N i k o l a j   G a m m e l t o f t
-- 2010-12-03T23:12:47Z
-- http://www.bloomberg.com/news/2010-12-03/human-genome-sciences-oshkosh-pfizer-u-s-equity-preview.html
Shares of the following companies may
have unusual moves in U.S. trading on Dec. 6. Stock symbols are
in parentheses.  Human Genome Sciences Inc.  (HGSI US): The Rockville,
Maryland-based drugmaker’s Benlysta, the first new treatment for
lupus in 52 years, needs more review by U.S. regulators before
it may be approved for sale. The Food and Drug Administration
extended the deadline for a decision to March 10. Human Genome
is developing the drug together with  GlaxoSmithKline Plc  (GSK
US).  Oshkosh Corp.  (OSK US): The maker of all-terrain blast-
proof trucks for the military was awarded a $413.2 million firm-
fixed-price contract for 1,800 family of medium tactical
vehicles for the Army National Guard, the U.S. Defense
Department said on its website.  Pfizer Inc.  (PFE US): The world’s biggest drugmaker plans
to seek regulatory approval next year in Europe and the U.S. to
sell bosutinib for patients with chronic myeloid leukemia.  To contact the reporter on this story:
 Nikolaj Gammeltoft  in New York at 
 ngammeltoft@bloomberg.net .  To contact the editor responsible for this story:
Nick Baker at   nbaker7@bloomberg.net  